Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

41. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics Full Text available with Trip Pro

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics The objective of this study was to compare persistence, costs, and healthcare resource utilization in patients with schizophrenia and cardiometabolic comorbidities treated with once-monthly paliperidone palmitate or an oral atypical antipsychotic.Medicaid data from six states (07/2009-03/2015) were used to identify (...) adults with schizophrenia and cardiometabolic comorbidities initiated on once-monthly paliperidone palmitate or an oral atypical antipsychotic (index date) on 01/2010 or after. Persistence to index medication at 12 months (no gap ≥ 90 days) was compared between patients taking once-monthly paliperidone palmitate and an oral atypical antipsychotic using Chi-squared tests. The 12-month post-index healthcare costs and healthcare resource utilization were compared using multivariate ordinary least

2018 Drugs - real world outcomes

42. Cariprazine (Reagila) for the treatment of schizophrenia

Cariprazine (Reagila) for the treatment of schizophrenia Cariprazine (Reagila®) for the treatment of schizophrenia | Report | National Health Care Institute You are here: Cariprazine (Reagila®) for the treatment of schizophrenia Search within English part of National Health Care Institute Search Cariprazine (Reagila®) for the treatment of schizophrenia The Minister of Health, Welfare and Sport (WVS) asked Zorginstituut Nederland (National Health Care Institute) to carry out a substantive (...) assessment of the medicinal product Reagila® to determine whether it can be included in the Medicine Reimbursement System (GVS). And if so, if Cariprazine (Reagila®) is interchangeable with a medicinal product that is already included in the GVS. Advice Reagila® is an atypical antipsychotic, registered for the treatment of schizophrenia in adult patients. Based on the criteria for interchangeability, the Zorginstituut concludes that Reagila® is interchangeable with drugs that are already included

2018 National Health Care Institute (Zorginstituut Nederland)

43. Causes and risk factors: Women with schizophrenia are at increased risk of breast cancer

Causes and risk factors: Women with schizophrenia are at increased risk of breast cancer Women with schizophrenia are at increased risk of breast cancer | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Women with schizophrenia are at increased risk of breast cancer Article Text Commentary Causes and risk factors Women with schizophrenia are at increased risk of breast cancer Alison R Yung 1 , 2 , Joseph Firth 1 , 3 Statistics from

2018 Evidence-Based Mental Health

44. Pharmacological interventions: Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia

Pharmacological interventions: Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) failure risk in patients with schizophrenia Article Text Commentary Pharmacological interventions Clozapine and long-acting injectable antipsychotics reduce hospitalisation and treatment failure risk in patients with schizophrenia Jose M Rubio 1 , 2 , 3 , Christoph U Correll 1 , 2 , 3 , 4 Statistics from Altmetric.com Commentary on: Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA

2018 Evidence-Based Mental Health

45. Pharmacological interventions: L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia

Pharmacological interventions: L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia Article Text Commentary Pharmacological interventions L-methylfolate cannot yet be recommended as an add-on treatment

2018 Evidence-Based Mental Health

46. Schizophrenia

Schizophrenia Schizophrenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Schizophrenia Last reviewed: February 2019 Last updated: June 2018 Summary An illness characterised by a co-occurrence of at least two of the following symptoms: hallucinations, delusions, disorganised speech, disorganised/catatonic behaviour, or negative symptoms occurring for a significant period of time during a 1-month period (...) and delusions to frank psychosis. Initially, patients are usually referred by family members. As the illness progresses, patients tend to self-refer or are brought in by a case manager or law enforcement officer. Antipsychotic therapy and psychosocial interventions are effective for most patients, but to varying degrees. Suicidal tendency is one of the most dangerous complications. The lifetime risk of suicide is around 5%. The risk is highest at the onset of the illness. Definition Schizophrenia

2018 BMJ Best Practice

47. Transcranial Magnetic Stimulation for Major Depression and Schizophrenia

Transcranial Magnetic Stimulation for Major Depression and Schizophrenia Transcranial Magnetic Stimulation for Major Depression and Schizophrenia An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017 An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017. This report was prepared by: Ma N, Atukorale Y, Duncan J, Marlow N, Cameron A Research and Evaluation, incorporating ASERNIP-S, Royal (...) www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Ma N, Atukorale Y, Marlow N, Duncan J, Cameron A (2017) Transcranial Magnetic Stimulation for major depression and schizophrenia: an Evidence Check brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Ministry of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily

2018 Sax Institute Evidence Check

48. Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V

Cariprazine (schizophrenia) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Cariprazin (Schizophrenie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A18-25 Cariprazine (schizophrenia) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-25 Version 1.0 Cariprazine (schizophrenia) 12 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cariprazine (schizophrenia) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

49. Second-generation antipsychotic injections for schizophrenia

Second-generation antipsychotic injections for schizophrenia '); } else { document.write(' '); } ACE | Second-generation antipsychotic injections for treating schizophrenia Search > > Second-generation antipsychotic injections for treating schizophrenia - Second-generation antipsychotic injections for treating schizophrenia Published on 1 October 2018 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has not recommended listing paliperidone or aripiprazole injections (...) on the Medication Assistance Fund (MAF) for treating schizophrenia, due to unacceptable cost-effectiveness compared with first-generation antipsychotic injections at the prices proposed by the manufacturers. Factors considered to inform the recommendations for subsidy Technology evaluation Point Item 1.1 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the technology evaluation of injectable second-generation antipsychotics (SGAs)—paliperidone and aripiprazole injections

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

50. N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) G1001C polymorphism and susceptibility to schizophrenia: A meta-analysis. (Abstract)

N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) G1001C polymorphism and susceptibility to schizophrenia: A meta-analysis. A comprehensive literature search was conducted to identify all case-control studies investigating the association between GRIN1 G1001C polymorphism and schizophrenia susceptibility (MIM: 138249; dbSNP: rs 11146020). A total of 6 eligible studies (including 1639 schizophrenia cases and 1489 controls) were identified for the meta-analysis. Including all studies (...) , there was significant heterogeneity between studies. In overall the GC (OR=1.00, 95 % CI: 0.0.85-1.19) and CC (OR=1.09, 95 % CI: 0.67-1.79) genotypes were not associated with schizophrenia risk compared with the GG genotype. In one study patients were diagnosed using DSM-IIIR criteria and in another study the genotypic frequencies of control subjects showed significant deviation from the expected frequencies according to the Hardy-Weinberg equilibrium. After excluding these studies from the meta-analysis

2017 EXCLI journal

51. Zuclopenthixol dihydrochloride for schizophrenia. Full Text available with Trip Pro

Zuclopenthixol dihydrochloride for schizophrenia. Oral zuclopenthixol dihydrochloride (Clopixol) is an anti-psychotic treatment for people with psychotic symptoms, especially those with schizophrenia. It is associated with neuroleptic malignant syndrome, a prolongation of the QTc interval, extra-pyramidal reactions, venous thromboembolism and may modify insulin and glucose responses.To determine the effects of zuclopenthixol dihydrochloride for treatment of schizophrenia.We searched (...) the Cochrane Schizophrenia Group's Trials Register (latest search 09 June 2015). There were no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) focusing on zuclopenthixol dihydrochloride for schizophrenia. We included trials meeting our inclusion criteria and reporting useable data.We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI

2017 Cochrane

52. Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses Full Text available with Trip Pro

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bipolar I disorder (Clinicaltrials.gov: NCT00628589, NCT00721955).To examine the five individual items (...) comprising the PANSS-EC and the percentage of patients achieving a clinical response (reduction of ≥40%) in PANSS-EC (Response-40) for these two studies.Response-40 was examined at the primary end-point (2 h) and over time.Response-40 and each PANSS-EC item score were statistically significant v. placebo at 2 h and at each assessment time point for both doses.Inhaled loxapine produced rapid improvement in agitated patients with schizophrenia or bipolar I disorder, achieving Response-40 at the first

2017 BJPsych open Controlled trial quality: uncertain

53. Individual differences in schizophrenia Full Text available with Trip Pro

Individual differences in schizophrenia Whether there are distinct subtypes of schizophrenia is an important issue to advance understanding and treatment of schizophrenia.To understand and treat individuals with schizophrenia, the aim was to advance understanding of differences between individuals, whether there are discrete subtypes, and how first-episode patients (FEP) may differ from multiple episode patients (MEP).These issues were analysed in 687 FEP and 1880 MEP with schizophrenia using (...) the Positive and Negative Syndrome Scale for (PANSS) schizophrenia before and after antipsychotic medication for 6 weeks.The seven Negative Symptoms were correlated with each other and with P2 (conceptual disorganisation), G13 (disturbance of volition), and G7 (motor retardation). The main difference between individuals was in the cluster of seven negative symptoms, which had a continuous unimodal distribution. Medication decreased the PANSS scores for all the symptoms, which were similar in the FEP

2017 BJPsych open

54. Treatment for Adults With Schizophrenia

Treatment for Adults With Schizophrenia Comparative Effectiveness Review Number 198 Treatments for Schizophrenia in Adults: A Systematic Review eComparative Effectiveness Review Number 198 Treatments for Schizophrenia in Adults: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00009-I Prepared by: Pacific Northwest Evidence-based Practice Center (...) Portland, OR Investigators: Marian S. McDonagh, Pharm.D. Tracy Dana, M.L.S. Shelley Selph, M.D., M.P.H. Emily B. Devine, Pharm.D., Ph.D., M.B.A. Amy Cantor, M.D., M.P.H. Christina Bougatsos, M.P.H. Ian Blazina, M.P.H. Sara Grusing, B.A. Rochelle Fu, Ph.D. Sarah L. Kopelovich, Ph.D. Maria Monroe-DeVita, Ph.D. Daniel W. Haupt, M.D. AHRQ Publication No. 17(18)-EHC031-EF October 2017 Key Messages Purpose of Review To evaluate treatments for schizophrenia. Key Messages • Olanzapine, aripiprazole

2017 Effective Health Care Program (AHRQ)

55. Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran Full Text available with Trip Pro

Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran Corpus Callosum (CC) plays a significant role in hemispheric communication and in lateralized brain function and behaviors. Structural abnormalities in the corpus callosum of schizophrenic patients were reported. However, previous studies regarding the relationship between morphology of CC in patients with schizophrenia and healthy people are controversial.To evaluate the morphological differences (...) group was splenial bulbosity. The length and area of the CC in patients with schizophrenia were less than those of the control group and were greater in men compared with women in both groups. Although there was a significant difference in the surface area of the CC between the schizophrenic and control groups (p<0.001), no significant difference was seen regarding the anteroposterior length of CC (p=0.75). Moreover, a significant correlation was found between the surface area and anteroposterior

2017 Electronic physician

56. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Full Text available with Trip Pro

Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Delivering the diagnosis of a serious illness is an important skill in most fields of medicine, including mental health. Research has found that communication skills can impact on a person's recall and understanding of the diagnosis, treatment options and prognosis. People may feel confused and perplexed when information about their illness is not communicated properly. Sharing information (...) diagnoses to people; however, little is known specifically for delivering a diagnosis of schizophrenia.To evaluate evidence from randomised controlled trials (RCTs) for the efficacy of different communication strategies used by clinicians to inform people about the diagnosis and outcome of schizophrenia compared with treatment as usual and to compare efficacy between different communication strategies.On 22 June 2015 and 29 June 2016, we searched the Cochrane Schizophrenia Group's Study-Based Register

2017 Cochrane

57. A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina Full Text available with Trip Pro

A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina Schizophrenia is considered a serious mental disorder that affects over 21 million people worldwide, and is associated with disability that frequently affects the patient's educational and working performance. In Argentina, two of the most widely used antipsychotics in the treatment of this disorder are haloperidol and risperidone. Both are provided free (...) to patients without health coverage in public healthcare facilities. In this paper we seek to review the clinical and economic benefits of prescribing psychotropic therapies based on haloperidol (a first-generation antipsychotic that is part of the butyrophenone group of drugs) versus risperidone [an atypical or second-generation antipsychotic (neuroleptic) drug] in adult patients who have been diagnosed with schizophrenia. To achieve this objective, an exhaustive search of relevant articles published

2017 PharmacoEconomics open

58. Obesity in individuals with schizophrenia: a case controlled study in Scotland Full Text available with Trip Pro

Obesity in individuals with schizophrenia: a case controlled study in Scotland Despite extensive clinical concern about rates of obesity in patients with schizophrenia, there is little evidence of the extent of this problem at a population level.To estimate levels of obesity in a national population sample by comparing patients with schizophrenia with matched controls.We calculated levels of obesity for each patient with schizophrenia from the national Primary Care Clinical Informatics Unit (...) database (n=4658) matched with age, gender and neighbourhood controls.We demonstrated a significant increased obesity hazard for the schizophrenia group using Cox regression analysis, with odds ratio (OR) of 1.94 (95% CI 1.81-2.10) (under the assumption of missing body mass index (BMI) indicating non-obesity) and OR=1.68 (95% CI 1.55-1.81) where no assumptions were made for missing BMI data.People with schizophrenia are at increased risk of being obese compared with controls matched by age, gender

2017 BJPsych open

59. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders Full Text available with Trip Pro

Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders The objective of this article is to identify best practices in the diagnosis and assessment of patients with schizophrenia spectrum and other psychotic disorders. The diagnosis and assessment may occur in a range of situations from the emergency room to the outpatient clinic and at different stages of the disorder. The focus may be on acute exacerbations of illness (...) , residual symptoms, levels of function, or changes in the response to treatment.A systematic search was conducted for guidelines published in the last 5 years for schizophrenia and schizophrenia spectrum disorders. The guidelines were rated by at least 2 raters, and recommendations adopted on the diagnosis and assessment were primarily drawn from the American Psychiatric Association practice guidelines for the psychiatric evaluation of adults and the National Institute for Health and Care Excellence

2017 CPG Infobase

60. Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth Full Text available with Trip Pro

Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices (...) in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders.A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings

2017 CPG Infobase